HOWL — Werewolf Therapeutics Income Statement
0.000.00%
Last trade - 00:00- $73.17m
- $22.68m
- $1.89m
Annual income statement for Werewolf Therapeutics, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 0 | 0 | 16.4 | 19.9 | 1.89 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 22.4 | 50.1 | 72.5 | 60.4 | 76 |
| Operating Profit | -22.4 | -50.1 | -56.1 | -40.5 | -74.1 |
| Total Net Non Operating Interest Income / Expense | |||||
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -15 | -50 | -53.8 | -37.4 | -70.5 |
| Net Income After Taxes | -15 | -50 | -53.8 | -37.4 | -70.5 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -15 | -50 | -53.8 | -37.4 | -70.5 |
| Adjustments to Net Income | |||||
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -28.2 | -202 | -53.8 | -37.4 | -70.5 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -1.02 | -7.39 | -1.86 | -1.05 | -1.61 |
| Dividends per Share |